Patents by Inventor Magid A. Abou-Gharbia

Magid A. Abou-Gharbia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases
    Patent number: 10131637
    Abstract: Disclosed are compounds of the class of 2-phenylacetamides that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), and methods of using these modulators to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: November 20, 2018
    Assignees: Shifa Biomedical Corporation, Temple University—Of The Commonwealth System of Higher Education
    Inventors: Sherin Salaheldin Abdel-Meguid, Magid Abou-Gharbia, Benjamin Blass, Wayne Childers, Nabil Elshourbagy, Victor Ghidu, Rogelio Martinez, Harold Meyers, Shaker A. Mousa
  • Beta lactams as modulators of glutamate uptake and methods for use thereof
    Patent number: 9975879
    Abstract: Pharmaceutical compositions of the invention comprise compounds, compositions, methods useful for the treatment of drug addiction, drug withdrawal, and diseases or conditions that involve dysregulation of glutamate homeostasis in it etiology.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: May 22, 2018
    Assignee: Temple University of the Commonwealth System of Higher Education
    Inventors: Magid Abou-Gharbia, Wayne E. Childers, Rogelio L. Martinez, Mercy M. Ramanjulu, Benjamin E. Blass
  • ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES
    Publication number: 20180079730
    Abstract: Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), and methods of using these modulators to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
    Type: Application
    Filed: December 1, 2017
    Publication date: March 22, 2018
    Inventors: Sherin Salaheldin Abdel-Meguid, Magid Abou-Gharbia, Benjamin Blass, Wayne Childers, Nabil Elshourbagy, Victor Ghidu, Rogelio Martinez, Harold Meyers, Shaker A. Mousa
  • NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE
    Publication number: 20180016261
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: September 27, 2017
    Publication date: January 18, 2018
    Applicant: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Daniel J. CANNEY, Benjamin E. BLASS, Rong GAO, Magid ABOU-GHARBIA
  • NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE
    Publication number: 20180016262
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: September 27, 2017
    Publication date: January 18, 2018
    Applicant: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Daniel J. CANNEY, Benjamin E. BLASS, Rong GAO, Magid ABOU-GHARBIA
  • 5-hydroxytryptamine receptor 7 activity modulators and their method of use
    Patent number: 9802924
    Abstract: Pharmaceiiticai compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: October 31, 2017
    Assignee: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia
  • Novel 5-Hydroxytryptamine Receptor 7 Activity Modulators and Their Method of Use
    Publication number: 20170298037
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: September 10, 2015
    Publication date: October 19, 2017
    Applicant: Temple University-Of the Commonwealth System of Higher Education
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia
  • PCSK9 Inhibitors and Methods of Use Thereof
    Publication number: 20170290806
    Abstract: The present invention relates to compositions and methods for treating lipid disorders in a subject. In one embodiment, the compositions of the present invention can be used to inhibit protease proprotein convertase subtilisin-like kexin type 9 (PCSK9). In another embodiment, the compositions of the present invention can be used to disrupt the protein-protein interaction between PCSK9 and low-density lipoprotein receptor (LDLR).
    Type: Application
    Filed: September 8, 2015
    Publication date: October 12, 2017
    Inventors: Magid Abou-Gharbia, Wayne E. Childers
  • Cytochrome P450 inhibitors and their method of use
    Patent number: 9725436
    Abstract: Embodiments of the present invention relate to novel cytochrome P450 inhibitors and pharmaceutical compositions thereof having a disease-modifying action in the treatment of diseases associated with the production of cortisol that include metabolic syndrome, obesity, headache, depression, hypertension, diabetes mellitus, Cushing's Syndrome, pseudo-Cushing syndrome, cognitive impairment, dementia, heart failure, renal failure, psoriasis, glaucoma, cardiovascular disease, cancer, stroke or incidentalomas.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: August 8, 2017
    Assignee: CORTENDO AB (PUBL)
    Inventors: Benjamin Eric Blass, Magid A Abou-Gharbia, Wayne E. Childers, Pravin Iyer, Joshodeep Boruwa
  • SSAT mRNA translation repression and activation
    Patent number: 9585380
    Abstract: The invention provides an isolated nucleic acid having a sequence encoding a spermidine/spermine acetyltransferase (“SSAT”), wherein translation of an mRNA comprising the encoded SSAT has increased basal translation and increased stimulated translation, compared to a wild-type mRNA encoding SSAT. Methods of use for the nucleic acid are also provided. Methods and compositions are also provided for reducing ischemia-reperfusion injury in organs or tissue for transplantation.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: March 7, 2017
    Assignee: TEMPLE UNIVERSITY—Of The Commonwealth System of Higher Education
    Inventors: Salim Merali, Oscar Mauricio Perez Leal, Magid Abou-Gharbia, Wayne E. Childers
  • Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2B activity modulators
    Patent number: 9464062
    Abstract: Pharmaceutical compositions of the invention comprise disubstituted oxazolidin-2-ones derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 2b activity.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: October 11, 2016
    Assignee: TEMPLE UNIVERSITY—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Daniel J. Canney, Richie R. Bhandare, Benjamin E. Blass, Magid Abou-Gharbia
  • FUNCTIONALIZED FURAN-2-SULFONAMIDES EXHIBITING ENDOTHELIAL LIPASE INHIBITION
    Publication number: 20160257672
    Abstract: The present invention relates to pharmaceutical compositions comprising furan-2-sulfonamide derivatives. The present invention further relates to methods of treatment of diseases or conditions associated with endothelial lipase activity, including coronary artery disease and low HDL-C.
    Type: Application
    Filed: October 6, 2014
    Publication date: September 8, 2016
    Inventors: Magid Abou-Gharbia, Wayne E. Childers, Rogelio Martinez, Victor P. Ghidu, Harold Meyers, Shaker A. Mousa, Nabil Elshourbagy
  • NOVEL FUNCTIONALIZED 5-(PHENOXYMETHYL)-1,3-DIOXANE ANALOGS EXHIBITING CYTOCHROME P450 INHIBITION AND THEIR METHOD OF USE
    Publication number: 20160244436
    Abstract: Pharmaceutical compositions described in this document comprise 5-(phenoxymethyl)-1,3-dioxane analogs having a disease-modifying action in the treatment of diseases associated with the production of cortisol that include metabolic syndrome, obesity, headache, depression, hypertension, diabetes mellitus, Cushing's Syndrome, pseudo-Cushing syndrome, cognitive impairment, dementia, heart failure, renal failure, psoriasis, glaucoma, cardiovascular disease, cancer, stroke, incidentalomas, or any diseases involving the overproduction of cortisol.
    Type: Application
    Filed: September 25, 2014
    Publication date: August 25, 2016
    Inventors: Benjamin Eric Blass, Magid A Abou-Gharbia, Wayne E. Childers, Pravin Iyer, Joshodeep Boruwa, Ramreddy Bobbala, Rajashekar Reddy Nimmareddy
  • NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF
    Publication number: 20160229841
    Abstract: Pharmaceutical compositions of the invention comprise compounds, compositions, methods useful for the treatment of drug addiction, drug withdrawal, and diseases or conditions that involve dysregulation of glutamate homeostasis in it etiology.
    Type: Application
    Filed: June 4, 2014
    Publication date: August 11, 2016
    Inventors: Magid ABOU-GHARBIA, Wayne E. CHILDERS, Rogelio L. MARTINEZ, Mercy M. RAMANJULU, Benjamin E. BLASS
  • NOVEL CYTOCHROME P450 INHIBITORS AND THEIR METHOD OF USE
    Publication number: 20160221990
    Abstract: Embodiments of the present invention relate to novel cytochrome P450 inhibitors and pharmaceutical compositions thereof having a disease-modifying action in the treatment of diseases associated with the production of cortisol that include metabolic syndrome, obesity, headache, depression, hypertension, diabetes mellitus, Cushing's Syndrome, pseudo-Cushing syndrome, cognitive impairment, dementia, heart failure, renal failure, psoriasis, glaucoma, cardiovascular disease, cancer, stroke or incidentalomas.
    Type: Application
    Filed: September 15, 2014
    Publication date: August 4, 2016
    Inventors: Benjamin Eric Blass, Magid A Abou-Gharbia, Wayne E. Childers, Pravin Iyer, Joshodeep Boruwa
  • NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE
    Publication number: 20160016941
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: March 11, 2014
    Publication date: January 21, 2016
    Applicant: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Daniel J. CANNEY, Benjamin E. BLASS, Rong GAO, Magid ABOU-GHARBIA
  • ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES
    Publication number: 20150376139
    Abstract: Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), and methods of using these modulators to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
    Type: Application
    Filed: March 11, 2014
    Publication date: December 31, 2015
    Inventors: Sherin Salaheldin Abdel-Meguid, Magid Abou-Gharbia, Benjamin Blass, Wayne Childers, Nabil Elshourbagy, Victor Ghidu, Rogelio Martinez, Harold Meyers, Shaker A. Mousa
  • NOVEL FUNCTIONALIZED 4-(PHENOXYMETHYL(-1,3-DIOXOLANE ANALOGS EXHIBITING CYTOCHROME P450 INHIBITION AND THEIR METHOD OF USE
    Publication number: 20150353530
    Abstract: Embodiments of the present invention relate to 4-(phenoxymethyl)-1,3-dioxolane analogs and pharmaceutical compositions thereof having a disease-modifying action in the treatment of diseases associated with the overproduction of cortisol that include metabolic syndrome, and any involving the overproduction of cortisol.
    Type: Application
    Filed: January 31, 2014
    Publication date: December 10, 2015
    Applicant: Cortendo AB (publ)
    Inventors: Benjamin Eric Blass, Magid A. Abou-Gharbia, Wayne E. Childers
  • DISUBSTITUTED OXAZOLIDIN-2-ONES 5-HYDROXYTRYPTAMINE RECEPTOR 2B ACTIVITY MODULATORS
    Publication number: 20150291539
    Abstract: Pharmaceutical compositions of the invention comprise disubstituted oxazolidin-2-ones derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 2b activity.
    Type: Application
    Filed: November 26, 2013
    Publication date: October 15, 2015
    Inventors: Daniel J. Canney, Richie R. Bhandare, Benjamin E. Blass, Magid Abou-Gharbia
  • NOVEL CYTOCHROME P450 INHIBITORS AND THEIR METHOD OF USE
    Publication number: 20150210641
    Abstract: Embodiments of the present invention relate to novel cytochrome P450 inhibitors and pharmaceutical compositions thereof having a disease-modifying action in the treatment of diseases associated with the overproduction of cortisol that include metabolic syndrome, and any involving the overproduction of cortisol.
    Type: Application
    Filed: January 13, 2015
    Publication date: July 30, 2015
    Inventors: Benjamin Eric Blass, Magid A. Abou-Gharbia, Wayne E. Childers, Mercy M. Ramanjulu, George Charles Morton